Silo Pharma, Inc. (SILO) Stock
SILO Key Statistics
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
CEO: Eric Weisblum. Company website
SILO — Frequently Asked Questions
What is the SILO stock price today?
Silo Pharma, Inc. (SILO) trades at $5.70, down 26.26% on the day, as of Nov 12, 2026 10:46 UTC.
What is Silo Pharma, Inc.'s market cap?
Silo Pharma, Inc. has a market capitalisation of $45.66M, calculated from the live SILO share price and shares outstanding.
What is the P/E ratio of SILO?
SILO has no meaningful price-to-earnings ratio: Silo Pharma, Inc. lost $0.61 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Silo Pharma, Inc. make?
Silo Pharma, Inc. generated revenue of $72,102.00 over the trailing twelve months, which puts the stock at 633.33 times sales.
What is the 52-week range for SILO?
SILO has traded between $4.35 and $10.43 over the past 52 weeks, and the last price is 45.3% below that high.
Is Silo Pharma, Inc. profitable?
No. Silo Pharma, Inc. is loss-making, with a net margin of -5,863.50% over the trailing twelve months.
What sector is Silo Pharma, Inc. in?
Silo Pharma, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Silo Pharma, Inc.?
Eric Weisblum is the chief executive of Silo Pharma, Inc., which employs 3 people.
Where can I track SILO in real time?
QFI Terminal shows SILO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SILO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SILO in Terminal See plans